SGTX Projected Dividend Yield

Sigilon Therapeutics Inc ( NASDAQ : SGTX )

Sigilon Therapeutics is a clinical stage biotechnology company developing a class of therapeutics and functional cures for patients with chronic diseases. Co.'s product candidates include: SIG-005, which treats the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease; SIG-007, which provides continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; SIG-002, which is designed to replace islet cells for the treatment of Type 1 Diabetes; and SIG-001, which prevents bleeding episodes in patients with moderate to severe Hemophilia A.

20 YEAR PERFORMANCE RESULTS